Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) Sees Significant Growth in Short Interest

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) was the recipient of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 2,538,952 shares, a growth of 21.0% from the January 29th total of 2,098,448 shares. Based on an average trading volume of 1,518,433 shares, the days-to-cover ratio is currently 1.7 days. Currently, 0.3% of the shares of the company are short sold. Currently, 0.3% of the shares of the company are short sold. Based on an average trading volume of 1,518,433 shares, the days-to-cover ratio is currently 1.7 days.

Elite Pharmaceuticals Stock Down 1.7%

Shares of Elite Pharmaceuticals stock opened at $0.38 on Wednesday. Elite Pharmaceuticals has a twelve month low of $0.27 and a twelve month high of $0.82. The company has a quick ratio of 5.44, a current ratio of 7.34 and a debt-to-equity ratio of 0.05. The company’s 50 day moving average is $0.44 and its 200 day moving average is $0.55. The company has a market cap of $414.11 million, a price-to-earnings ratio of 12.82 and a beta of 0.35.

Elite Pharmaceuticals (OTCMKTS:ELTP) last announced its earnings results on Tuesday, February 17th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter. The business had revenue of $31.59 million during the quarter. Elite Pharmaceuticals had a net margin of 30.98% and a return on equity of 47.93%.

Elite Pharmaceuticals Company Profile

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.